High stock market volatility … will persist until the RegMed universe offers … news; stimulating … attractive near and long-term returns.
This is not … currently … a feel good environment … but, quarterly earnings are coming (even though – LPS <loss per share> might NOT be good – however, quarterly milstone attainment is happening - albiet quietly and advancement of development … should highlight … future appreciation. Also, cash positions remain what they are … but, most runways are … enough through 2012 … when markets return or better, partners emerge!!
Notice … trials are still … being announced while others are continuing or being recruited … again quietly … new team members are being recruited … I have seen … NO … failures announced (so, risk profiles remain the same or positive)!
I have also … not seen so many lows … with less EU “tear gas” and debt politics … transition is upon us. Faith is NOT a measureable factor but … I percieve BETTER days … for our universe and portfolios!!
Mid-Day: The NASDAQ is DOWN -17.20 (-0.65%) to 2,640.23. The Dow is UP +24.37 (+0.21%) to 11,601.42.
Mid-Day Movers: BioMimetic (NASDAQ:BMTI), BioTime (AMex: BTX), Dendreon (NASDAQ:DNDN), Geron (NASDAQ:GERN), International Stem Cell (OTC BB: ISCO), Neuralstem (AMEX: CUR), Opexa (OPXA), Pluristem (NASDAQ:PSTI), ReNeuron (RENE.LON) and Tengion (TNGN)
What’s new in the regenerative medicine/stem cell market …
NeoStem’s (AMEX: NBS) Progenitor Cell Therapy (PCT) adds to Management to meet Demand: Industry veterans join PCT to assist client-focused development, manufacturing and growing portfolio of cellular therapeutic candidates. The bottom Line: Dr. Fong and Dr. O’Neill lend their expertise to PCT’s clients and to NBS’ preclinical and clinical development programs. These additions enable their expanding client base. http://www.scimitarequity.com/blog/2011/10/19/neostem%e2%80%99s-amex-nbs-progenitor-cell-therapy-pct-adds-to-management-to-meet-demand
Abbott Laboratories announced plans this morning to split itself in 2, spinning off its $18B pharmaceuticals arm under a new name. The bottom line, that should signal trouble to investors in other drug companies like Pfizer, Merck, and Bristol-Myers Squibb, because it signals that pharmaceuticals is becoming a lot less appealing as a business. Investors cheered the plan, bidding shares up 5% to $55, close to the stock’s 52-week high. http://www.forbes.com/sites/matthewherper/2011/10/19/abbott-ditches-its-drug-business